Advertisement
AXON vs VCYT
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Veracyte (VCYT) Stock Comparison
Key Takeaways
- Axon Enterprise (AXON), a leader in public safety technology, shows robust year-to-date gains of about 29%, outpacing Veracyte (VCYT)'s 21% rise, amid recent market volatility.
- AXON commands a massive $32 billion market cap with strong analyst buy ratings and growth forecasts of 27-30% revenue, contrasting VCYT's $2.6 billion valuation in genomics diagnostics.
- Recent weeks saw AXON pull back from peaks near $880 to around $400, driven by debt concerns and sector rotations, while VCYT rallied above its 50-day moving average.
- Analysts project higher upside for AXON with average targets near $700, versus VCYT's $46, reflecting divergent sector tailwinds.
- Both stocks exhibit high P/E ratios—AXON at 263 (price-to-earnings) and VCYT at 40—signaling growth premiums in distinct industries.
Introduction
This comparison pits Axon Enterprise (AXON), a pioneer in public safety hardware and SaaS (software-as-a-service) solutions, against Veracyte (VCYT), a genomics diagnostics firm advancing cancer detection. Traders eyeing technology-driven growth and healthcare innovation, or investors assessing relative performance amid market shifts, will find value here. With both stocks posting solid year-to-date returns but facing distinct headwinds, this analysis highlights price behavior, sentiment, and positioning in the current environment.
AXON Overview and Recent Performance
Axon Enterprise (AXON) develops TASER conducted energy devices, body cameras, and cloud-based evidence management software for law enforcement. In recent market activity, the stock has traded around $400, down sharply from its 52-week high above $880 but up 29% year-to-date and 35% over the past year. Momentum softened in recent weeks with a roughly 7% monthly decline, influenced by broader sector rotations, rising debt worries, and profit-taking after strong Q4 results showing 40% SaaS revenue growth. Positive catalysts include AI integrations like an AI-powered 911 platform and 27-30% revenue guidance for the year, bolstering sentiment despite elevated valuations.
VCYT Overview and Recent Performance
Veracyte (VCYT) specializes in genomic tests like Afirma for thyroid cancer and Decipher for prostate and bladder diagnostics. Shares hover near $33, within a 52-week range of $23 to $51, with year-to-date gains of 21% and 11% over the past year. Recent weeks brought upward momentum, with rallies of 6-14% noted as the stock broke above its 50-day moving average, supported by steady volume and analyst adjustments. Sentiment reflects optimism in diagnostics demand, though tempered by valuation scrutiny and mixed returns earlier in the period.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top 25 AI-powered trading bots from a library of 351, curated for current market conditions across stocks, ETFs, and crypto. These bots employ machine learning for real-time signals, featuring diverse strategies like trend following, dip buying, and multi-agent systems with risk controls such as 2-3% take-profit and 2-10% stop-loss corridors. Performance stats impress: annualized returns from +24% to +163%, win rates of 51-88%, profit factors up to 11.7, and profit-to-drawdown ratios averaging 8. Traders can copy these virtually with no minimums, targeting sectors from semiconductors to industrials. Explore these high performers to enhance your strategy in volatile markets.
Head-to-Head Comparison
Axon Enterprise (AXON) and Veracyte (VCYT) operate in disparate arenas: public safety tech versus precision oncology diagnostics, leading to contrasting growth drivers. AXON benefits from recurring SaaS revenue (40% growth recently) and AI expansions, but faces higher volatility and debt risks, with a sky-high P/E signaling aggressive expansion bets. VCYT offers more stable healthcare exposure, lower P/E, and recent technical breakouts, yet contends with reimbursement hurdles and slower revenue scaling. Momentum favors VCYT short-term, while AXON leads in market cap, analyst conviction, and long-term catalysts. Sector sentiment tilts toward defense tech amid geopolitical tensions, versus biotech's regulatory sensitivities.
Tickeron AI Verdict
Tickeron’s AI models currently lean toward Axon Enterprise (AXON), citing superior trend consistency, expansive catalysts like AI public safety tools, and elevated analyst targets implying 75% upside potential. Veracyte (VCYT) shows promise in recent momentum and diagnostics stability, but trails in scale and growth trajectory. This positioning suggests higher probability of outperformance for AXON in prevailing conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Buy and VCYT is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green whileVCYT’s FA Score has 0 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- VCYT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while VCYT’s TA Score has 6 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 6 bearish.
- VCYT’s TA Score: 6 bullish, 5 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -9.13% price change this week, while VCYT (@Medical Specialties) price change was -2.87% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -1.16%. For the same industry, the average monthly price growth was +2.06%, and the average quarterly price growth was +17.36%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.27%. For the same industry, the average monthly price growth was +8.03%, and the average quarterly price growth was -5.20%.
Reported Earning Dates
AXON is expected to report earnings on Aug 11, 2026.
VCYT is expected to report earnings on Aug 11, 2026.
Industries' Descriptions
@Aerospace & Defense (-1.16% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Medical Specialties (-0.27% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| AXON | VCYT | AXON / VCYT | |
| Capitalization | 35.6B | 3.78B | 943% |
| EBITDA | 320M | 112M | 286% |
| Gain YTD | -22.221 | 12.423 | -179% |
| P/E Ratio | 178.12 | 43.82 | 406% |
| Revenue | 2.98B | 542M | 550% |
| Total Cash | 737M | 439M | 168% |
| Total Debt | 1.83B | 39.3M | 4,651% |
AXON | VCYT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 68 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 58 Fair valued | |
PROFIT vs RISK RATING 1..100 | 66 | 80 | |
SMR RATING 1..100 | 82 | 81 | |
PRICE GROWTH RATING 1..100 | 60 | 38 | |
P/E GROWTH RATING 1..100 | 58 | 81 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VCYT's Valuation (58) in the Biotechnology industry is in the same range as AXON (78). This means that VCYT’s stock grew similarly to AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (66) in the Biotechnology industry is in the same range as VCYT (80). This means that AXON’s stock grew similarly to VCYT’s over the last 12 months.
VCYT's SMR Rating (81) in the Biotechnology industry is in the same range as AXON (82). This means that VCYT’s stock grew similarly to AXON’s over the last 12 months.
VCYT's Price Growth Rating (38) in the Biotechnology industry is in the same range as AXON (60). This means that VCYT’s stock grew similarly to AXON’s over the last 12 months.
AXON's P/E Growth Rating (58) in the Biotechnology industry is in the same range as VCYT (81). This means that AXON’s stock grew similarly to VCYT’s over the last 12 months.
| AXON | VCYT | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 59% | 3 days ago 68% |
| Stochastic ODDS (%) | 3 days ago 69% | 3 days ago 81% |
| Momentum ODDS (%) | 3 days ago 72% | 3 days ago 73% |
| MACD ODDS (%) | 3 days ago 83% | 3 days ago 78% |
| TrendWeek ODDS (%) | 3 days ago 67% | 3 days ago 81% |
| TrendMonth ODDS (%) | 3 days ago 72% | 3 days ago 80% |
| Advances ODDS (%) | 13 days ago 74% | 11 days ago 73% |
| Declines ODDS (%) | 3 days ago 69% | 3 days ago 80% |
| BollingerBands ODDS (%) | 3 days ago 69% | 7 days ago 82% |
| Aroon ODDS (%) | 3 days ago 71% | 3 days ago 81% |
Advertisement
VCYT and
Correlation & Price change
A.I.dvisor indicates that over the last year, VCYT has been closely correlated with NTLA. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if VCYT jumps, then NTLA could also see price increases.
| Ticker / NAME | Correlation To VCYT | 1D Price Change % | ||
|---|---|---|---|---|
| VCYT | 100% | -0.19% | ||
| NTLA - VCYT | 69% Closely correlated | -1.94% | ||
| VCEL - VCYT | 60% Loosely correlated | -2.88% | ||
| AXON - VCYT | 58% Loosely correlated | -1.00% | ||
| DNA - VCYT | 57% Loosely correlated | -1.38% | ||
| ABCL - VCYT | 55% Loosely correlated | -0.57% | ||
More | ||||